Targeted induction of mitochondrial stress can enhance innate immune activation in GBM, potentially reducing recurrence (ref: Han doi.org/10.1002/adma.202511351/).
Extrachromosomal DNA contributes to oncogene spatial heterogeneity and evolution in GBM, impacting treatment resistance (ref: Noorani doi.org/10.1158/2159-8290.CD-24-1555/).
A self-homing liposomal nanobot effectively delivers chemotherapy in GBM by navigating the tumor microenvironment (ref: Cheng doi.org/10.1002/anie.202512948/).
ENPP1 is a promising target for enhancing innate immune checkpoint blockade responses in GBM (ref: Wang doi.org/10.1016/j.xcrm.2025.102336/).
Hydrogen sulfide therapy improves survival by inhibiting tumor-associated macrophage recruitment in GBM (ref: Camarano doi.org/10.1016/j.redox.2025.103866/).
A new nomogram for GBM prognosis incorporates risk factors to assist in personalized treatment approaches (ref: Wu doi.org/10.3389/fimmu.2025.1642107/).